Cancer Institute, University of Mississippi Medical Center, Jackson, MS, USA.
Institut National de la Santé et de la Recherche Médicale, U 977, University of Strasbourg, 67000 Strasbourg, France; Department of Operative Dentistry and Endodontics, Dental Faculty, University of Strasbourg, 67000 Strasbourg, France.
Cancer Lett. 2014 Feb 1;343(1):123-33. doi: 10.1016/j.canlet.2013.09.024. Epub 2013 Sep 27.
The presence and the involvement of cancer stem-like cells (CSCs) in tumor initiation and progression, and chemo-resistance are documented. Herein, we functionally analyzed melanoma stem-like cells (MSC)/CD133(+) cells on their resistance and response to taxol-induced apoptosis. Besides being taxol resistant, the CD133(+) cells demonstrated a growth advantage over the CD133(-) subpopulation. Taxol induced apoptosis on CD133(-) cells, but not on CD133(+) cells. In the CD133(-) subpopulation, the exposure to taxol induced the activation of apoptosis signal-regulating kinase1 (ASK1)/c-jun-N-terminal kinase (JNK), p38, extracellular signal regulated kinase (ERK) pathways and Bax expression, while in CD133(+) cells taxol was able only to enhance the activity of the ERK pathway. In CD133(+) cells, the direct gene transfer of Bax overcame the acquired resistance to taxol. Taken together, our data provide an insight into the mechanistic cascade of melanoma resistance to taxol and suggest Bax gene transfer as a complementary approach to chemotherapy.
肿瘤起始和进展过程中存在癌症干细胞样细胞(CSC),且其具有化疗耐药性,这一点已得到证实。在此,我们对黑色素瘤干细胞样细胞(MSC)/CD133(+)细胞进行了功能分析,以研究其对紫杉醇诱导细胞凋亡的耐药性和反应。除了对紫杉醇耐药外,CD133(+)细胞的生长优势也强于 CD133(-)亚群。紫杉醇诱导 CD133(-)细胞凋亡,但不能诱导 CD133(+)细胞凋亡。在 CD133(-)亚群中,紫杉醇诱导凋亡信号调节激酶 1(ASK1)/c-jun-N 末端激酶(JNK)、p38、细胞外信号调节激酶(ERK)通路和 Bax 表达的激活,而在 CD133(+)细胞中,紫杉醇只能增强 ERK 通路的活性。在 CD133(+)细胞中,Bax 的直接基因转移克服了对紫杉醇的获得性耐药。综上所述,我们的数据为黑色素瘤对紫杉醇耐药的机制级联提供了深入了解,并提示 Bax 基因转移可作为化疗的补充方法。